Recently, Vision Medicals announced a successful completion of D+ round funding worth hundreds of millions RMB, with Kequan Fund as lead-investor and Tianxin Fund as co-investor. Funds raised in this round will be primarily used to promote the research and development of pathogen molecular precision diagnosis products and their transformation into IVD products, accelerating the implementation of comprehensive solutions in top medical institutions across the country. At the same time, Vision Medicals will establish a new advanced production base for molecular diagnostic reagents and instruments.

Following the B and C rounds of funding, CEC Capital has continued to serve Vision Medicals as exclusive financial advisor in this transaction.

Founded in 2018, Vision Medicals focuses on genetic diagnosis and infection precision medicine. The company strives to build an AI diagnosis system for infectious diseases based on genomics, imaging omics, and EMR big data, providing comprehensive solutions for precise infectious disease diagnosis in clinical settings. The company has established a research and development center, medical laboratory, and GMP production base for in vitro diagnostic products covering an area of over 10,000 square meters. It also has testing centers and branches in Beijing, Shanghai, Guangzhou, Zhengzhou, Chengdu, and other locations. The company has accumulated large sample data of over 400,000 cases of pathogenic metagenomics and has participated in the early detection and identification of major pathogens such as COVID-19.